SCHEMBL24723817

SCHEMBL24723817

CNc1ccccc1Oc1cccc(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MTNR1B P49286 3/20 0.58
PYGM P11217 1/20 0.48
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 1/20 0.42
LMNA P02545 1/20 0.42
MTNR1A P48039 1/20 0.42
GAA P10253 1/20 0.42
APP P05067 1/20 0.41
PGR P06401 2/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24683905 0.81 MAOB (0.55) MTNR1BPOLBSMN1; SMN2MEN1KMT2A
SCHEMBL1341786 0.81 TSHR (0.58) KDM4EPOLBL3MBTL1MAPTNPSR1
SCHEMBL13791510 0.80 MAPK1 (0.65) MTNR1BKDM4EPOLBSMN1; SMN2L3MBTL1
SCHEMBL26270864 0.77 MTNR1B (0.73) MTNR1BPYGMKDM4EPOLBSMN1; SMN2
SCHEMBL6240378 0.77 APP (0.48) KDM4EPOLBSMN1; SMN2L3MBTL1MAPT
SCHEMBL26218878 0.77 MEN1 (0.56) MTNR1BPOLBSMN1; SMN2MEN1KMT2A
SCHEMBL5609585 0.77 AR (0.55) MTNR1BKDM4EPOLBSMN1; SMN2MEN1
SCHEMBL8145865 0.76 MTNR1B (0.65) MTNR1BPYGMPOLBMEN1KMT2A
SCHEMBL25386995 0.75 MTNR1B (0.75) MTNR1BPYGMKDM4EPOLBSMN1; SMN2
SCHEMBL5537634 0.75 KDM4E (0.49) MTNR1BKDM4EPOLBSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022232509-A1 PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT CITY OF HOPE (US) 2022-11-03 WO disclosed